MCC-DM1 (CAS 1228105-53-0)
QUICK LINKS
MCC-DM1, a complex chemical conjugate, operates through a sophisticated mechanism primarily utilized in cancer research. The core component, DM1, is a potent microtubule inhibitor, derived from maytansine, which disrupts microtubule dynamics by binding to tubulin at the maytansine-binding site. This disruption prevents the assembly of microtubules, an essential process for cell division, thereby selectively inhibiting the proliferation of rapidly dividing cancer cells. The MCC (maleimidocaproyl) linker connects DM1 to antibodies or other targeting molecules, enabling the precise delivery of DM1 to cancer cells. This targeted approach minimizes the impact on normal, healthy cells, enhancing the specificity of cancer research models. The conjugation technology behind MCC-DM1 is pivotal in the development of antibody-drug conjugates (ADCs), offering a platform for studying the targeted delivery of cytotoxic agents to cancer cells, elucidating the cellular processes influenced by microtubule inhibition, and exploring the potential of harnessing the body′s immune system to fight cancer.
MCC-DM1 (CAS 1228105-53-0) References
- Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. | Polson, AG., et al. 2009. Cancer Res. 69: 2358-64. PMID: 19258515
- Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. | Shen, BQ., et al. 2012. Curr Drug Metab. 13: 901-10. PMID: 22475269
- Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate. | Corrigan, PA., et al. 2014. Ann Pharmacother. 48: 1484-93. PMID: 25082874
- Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). | Uppal, H., et al. 2015. Clin Cancer Res. 21: 123-33. PMID: 25370470
- Current ADC Linker Chemistry. | Jain, N., et al. 2015. Pharm Res. 32: 3526-40. PMID: 25759187
- Analysis of small molecule antibody-drug conjugate catabolites in rat liver and tumor tissue by liquid extraction surface analysis micro-capillary liquid chromatography/tandem mass spectrometry. | Lanshoeft, C., et al. 2016. Rapid Commun Mass Spectrom. 30: 823-32. PMID: 26969923
- Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1). | Singh, AP., et al. 2016. AAPS J. 18: 861-75. PMID: 27029797
- New Insights in Tissue Distribution, Metabolism, and Excretion of [3H]-Labeled Antibody Maytansinoid Conjugates in Female Tumor-Bearing Nude Rats. | Walles, M., et al. 2016. Drug Metab Dispos. 44: 897-910. PMID: 27122302
- Structural Characterization of Cross-Linked Species in Trastuzumab Emtansine (Kadcyla). | Chen, Y., et al. 2016. Bioconjug Chem. 27: 2037-47. PMID: 27458087
- LC-MS/MS method for the simultaneous determination of Lys-MCC-DM1, MCC-DM1 and DM1 as potential intracellular catabolites of the antibody-drug conjugate trastuzumab emtansine (T-DM1). | Liu, Y., et al. 2017. J Pharm Biomed Anal. 137: 170-177. PMID: 28131055
- Study on the Heterogeneity of T-DM1 and the Analysis of the Unconjugated Linker Structure under a Stable Conjugation Process. | Wu, G., et al. 2019. ACS Omega. 4: 8834-8845. PMID: 31459971
- Simple and Rapid LC-MS/MS Methods for Quantifying Catabolites of Antibody-Drug Conjugates with SMCC Linker. | Li, L., et al. 2021. J Chromatogr Sci. 59: 642-649. PMID: 33420505
- Detection and Characterization of In Vitro Payload-Containing Catabolites of Noncleavable Antibody-Drug Conjugates by High-Resolution Mass Spectrometry and Multiple Data Mining Tools. | Cai, T., et al. 2023. Drug Metab Dispos. 51: 591-598. PMID: 36707253
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MCC-DM1, 0.5 mg | sc-488035 | 0.5 mg | $390.00 | |||
MCC-DM1, 5 mg | sc-488035A | 5 mg | $2800.00 |